Product Reports Resources Pricing Login Book a demo

Limbix

Biotech & Life Sciences · Palo Alto, United States · Founded 2016

Prescription digital therapeutics for adolescent mental health MoreLess

Founded in 2016 by Ben Lewis and Jon Sockell, Limbix operates at the intersection of technology and adolescent mental health. Lewis, with a background as an Engineering Manager at Facebook and founder of two other companies, and Sockell, a former Director of Marketing, established the company to address the critical need for accessible mental health treatments for young people. The company initially explored virtual reality for exposure therapy but pivoted in late 2019 to focus on mobile-based digital therapeutics. After raising a total of $31 million over several funding rounds, with notable contributions from investors like GSR Ventures and Sequoia Capital, Limbix was acquired by Big Health in July 2023.

Limbix develops prescription digital therapeutics (PDTs), which are software-based interventions prescribed by healthcare professionals to treat medical conditions. The company's business model targets health systems and payors, aiming to integrate its products into the existing healthcare framework as a new, evidence-based treatment option. This approach allows clinicians to prescribe the digital tools as an adjunct to traditional therapy for adolescents aged 13 to 22.

The company's flagship product is SparkRx, a smartphone application designed to help manage symptoms of adolescent depression. SparkRx is a multi-week, self-guided program based on the principles of Cognitive Behavioral Therapy (CBT), with a specific focus on behavioral activation. It uses features like mood tracking, problem-solving exercises, mindfulness activities, and a supportive chatbot named 'Limbot' to teach users coping skills and the relationship between their mood and actions. Clinical studies have shown that SparkRx can lead to a statistically significant reduction in depression symptoms. The product was launched under an FDA enforcement policy related to the COVID-19 pandemic, which permitted marketing without full FDA clearance to improve access to psychiatric digital health devices.

Keywords: prescription digital therapeutics, adolescent mental health, cognitive behavioral therapy, behavioral activation, mobile health, digital mental health, SparkRx, teen depression, youth mental wellness, clinical psychology, digital intervention, healthcare technology, telemedicine, behavioral health, acquired, Big Health, Ben Lewis, Jon Sockell, mental health treatment, pediatric mental health

Company overview

Limbix company information

The essential company record, classifications and operating signals in one place.

Status
Acquired
Founded
2016
Headquarters
Palo Alto, United States
Employees
5
Open positions
None listed
Dealroom signal
50.5
client focusb2bsub industryPharmaceuticalsub industryMedical Devicessub industryHealth Platformbusiness modelManufacturingindustryHealthsectorBiotechnologysectorMental HealthsectorPatient CaresectorDigital TherapeuticssectorTech for Biotech and PharmasectorTech for PatientssectorBiotech and PharmasectorCognitive Behavioural Therapy

Valuation & funding

Limbix funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONExit Jul 2023 $0 Big Health
SERIES AEquity / VC Dec 2021 $15M $60M Digital Garage · Storm Ventures · Bixink · DN Capital
SERIES AEquity / VC May 2020 $9M $36M GSR Ventures · Storm Ventures · NextGen Venture Partners · Sequoia
EARLY VCEquity / VC Dec 2019 $0 Undisclosed
SERIES AEquity / VC Apr 2018 $4M $16M Storm Ventures · Plug and Play
SEEDEquity / VC Dec 2016 Maverick Ventures
SEEDEquity / VC Nov 2016 Avichal Garg · Sequoia
Showing 7 recorded eventsUnlock the complete deal history →

Financials

Workforce over time

Available workforce history. Financial fields without reported data are omitted.

YearEmployees
2026 5
2025 4
2024 49
2023 49
2022 42
2021 40
2020 21
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Limbix website traffic

Latest recorded traffic for Limbix is 1.9K monthly website visits, down 13.6% over the last three months. Limbix's team grew 25% over the past year.

Latest monthly visits1.9K 3-month web change-13.6% 1-year team growth+25%
Monthly website visits90 observations · Jun 2018–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Limbix compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Limbix's talent

Book a demo to see the people
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

30 investors on Limbix's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 3 investors entered at this stage
Series A 7 investors entered at this stage
Other known 20 additional known investors
Big Health
Adventure Fund
Anorak Ventures
Carbon Arrow
DG Daiwa Ventures
E&Investment
For Good Ventures
Innovation Global Capital
JAZZ Venture Partners
KidsX
Levelup Investments
Mana Ventures
MassChallenge
Mo Z.
MVP Ventures
Operator Partners
Pathbreaker Ventures
Ryan Gembala
Small Business Innovation Research
Southwest-Midwest National Pediatric Device Innovation Consortium

Global footprint

Where Limbix has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

In the news

Latest news about Limbix

Recent press, funding announcements, and product moves mentioning Limbix — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Limbix

An AI-synthesized read of the highest-engagement posts about Limbix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Limbix’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.